123 related articles for article (PubMed ID: 38736583)
1. Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic.
Rath L; Yeh WZ; Roldan A; Wesselingh R; Zhong M; Tan T; Seery N; Bridge F; Foong Y; Skibina O; Nesbitt C; Butzkueven H; Monif M; van der Walt A
BMJ Neurol Open; 2024; 6(1):e000667. PubMed ID: 38736583
[TBL] [Abstract][Full Text] [Related]
2. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
[TBL] [Abstract][Full Text] [Related]
3. Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak.
You J; Tian J; Wu H; Kang W; Wen J; Xu H; Shi W; Wang Z; Wei H; Du Y; Li X; Mu G; Zhou M; Gu Z; Qu J
Expert Rev Anti Infect Ther; 2023; 21(12):1365-1371. PubMed ID: 37855094
[TBL] [Abstract][Full Text] [Related]
4. Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study.
Jakimovski D; Eckert SP; Mirmosayyeb O; Thapa S; Pennington P; Hojnacki D; Weinstock-Guttman B
Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851227
[TBL] [Abstract][Full Text] [Related]
5. Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan.
Kawashima I; Hyuga H; Nakadate A; Matsuura M; Sakamoto Y; Suzuki J; Kumagai T; Suzuki M; Koshiishi M; Yamamoto T; Nakajima K; Tanaka M; Kirito K
Int J Hematol; 2023 Dec; 118(6):731-736. PubMed ID: 37747583
[TBL] [Abstract][Full Text] [Related]
6. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
Nguyen Y; Flahault A; Chavarot N; Melenotte C; Cheminant M; Deschamps P; Carlier N; Lafont E; Thomas M; Flamarion E; Lebeaux D; Charlier C; Rachline A; Guérin C; Ratiney R; Touchard J; Péré H; Rozenberg F; Lanternier F; Arlet JB; Avouac J; Boussaud V; Guillemain R; Vignon M; Thervet E; Scemla A; Weiss L; Mouthon L;
Clin Microbiol Infect; 2022 Dec; 28(12):1654.e1-1654.e4. PubMed ID: 35926762
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
Montgomery H; Hobbs FDR; Padilla F; Arbetter D; Templeton A; Seegobin S; Kim K; Campos JAS; Arends RH; Brodek BH; Brooks D; Garbes P; Jimenez J; Koh GCKW; Padilla KW; Streicher K; Viani RM; Alagappan V; Pangalos MN; Esser MT;
Lancet Respir Med; 2022 Oct; 10(10):985-996. PubMed ID: 35688164
[TBL] [Abstract][Full Text] [Related]
8. Tixagevimab/Cilgavimab does not prevent COVID-19 in patients with multiple sclerosis and related disorders on B-cell depleting therapies.
Conway S; Gupta S; Healy B; Chuang TY; Stazzone L; Sullivan J; Polgar-Turcsanyi M; Chitnis T; Houtchens M
Mult Scler Relat Disord; 2024 Jul; 87():105680. PubMed ID: 38795595
[TBL] [Abstract][Full Text] [Related]
9. Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.
Young-Xu Y; Epstein L; Marconi VC; Davey V; Korves C; Zwain G; Smith J; Cunningham F; Bonomo RA; Ginde AA
mBio; 2023 Aug; 14(4):e0102423. PubMed ID: 37535398
[TBL] [Abstract][Full Text] [Related]
10. Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
Hobbs FDR; Montgomery H; Padilla F; Simón-Campos JA; Kim K; Arbetter D; Padilla KW; Reddy VP; Seegobin S; Streicher K; Templeton A; Viani RM; Johnsson E; Koh GCKW; Esser MT
Infect Dis Ther; 2023 Sep; 12(9):2269-2287. PubMed ID: 37751015
[TBL] [Abstract][Full Text] [Related]
11. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.
Ustianowski A
Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1517-1527. PubMed ID: 36217836
[TBL] [Abstract][Full Text] [Related]
12. [Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies].
Roppelt AA; Lebedkina MS; Chernov AA; Kruglova TS; Mukhina OA; Yukhnovskaya YD; Samedova FA; Mаrkina UA; Andrenova GV; Karaulov AV; Lysenko MA; Fomina DS
Ter Arkh; 2023 Feb; 95(1):78-84. PubMed ID: 37167118
[TBL] [Abstract][Full Text] [Related]
13. Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.
Angotzi F; Petrella M; Berno T; Binotto G; Bonetto G; Branca A; Carraro M; Cavaretta CA; Cellini A; D'Amore F; Forlani L; Gianesello I; Gurrieri C; Imbergamo S; Lessi F; Maroccia A; Mazzetto F; Pavan L; Pezone S; Piazza F; Pravato S; Ruocco V; Scapinello G; Vianello F; Zambello R; Zatta I; Zoletto S; Padoan A; Trentin L; Visentin A
Front Oncol; 2023; 13():1212752. PubMed ID: 37427126
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Intramuscular Tixagevimab-Cilgavimab in Prevention of COVID-19 in Patients Who Are Immunocompromised.
Moon R; Tien A; Chung J; Pinnelas R; Lee R; Hwang J; Brasfield F; Sahota A
Perm J; 2023 Dec; 27(4):44-54. PubMed ID: 37718610
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder.
Stastna D; Vachova M; Dusek P; Fistravec G; Drahota J; Menkyova I; Varju E; Horakova D; Kubala Havrdova E; Nytrova P
Mult Scler Relat Disord; 2024 May; 85():105523. PubMed ID: 38452649
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab.
Sciascia S; Rilat MLA; Fenoglio R; Foddai SG; Radin M; Cecchi I; Cinnirella G; Crosasso P; Guidetti MG; Barinotti A; Baldovino S; Menegatti E; Roccatello D
Clin Kidney J; 2023 Sep; 16(9):1465-1468. PubMed ID: 37664578
[TBL] [Abstract][Full Text] [Related]
17. Tixagevimab and Cilgavimab Administration for Hemodialysis Patients at Community-Based Dialysis Centers in Singapore as Pre-Exposure Prophylaxis for SARS-CoV-2 Infection.
Khan BA; Pagsinohin M; Lu LM; Tan P; Teo R
Cureus; 2023 Jul; 15(7):e41297. PubMed ID: 37539406
[TBL] [Abstract][Full Text] [Related]
18. Implementation of AZD7442 (Tixagevimab/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups.
Hayek S; Levy J; Shaham G; Dagan N; Serby D; Duskin-Bitan H; Yarden A; Ferreira C; Livnat I; Dube S; Taylor S; Venkatesan S; Balicer RD; Netzer D; Peretz A
Infect Dis Ther; 2024 Jun; 13(6):1379-1389. PubMed ID: 38728006
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis.
Soeroto AY; Yanto TA; Kurniawan A; Hariyanto TI
Rev Med Virol; 2023 Mar; 33(2):e2420. PubMed ID: 36617704
[TBL] [Abstract][Full Text] [Related]
20. Tixagevimab/cilgavimab (AZD7442/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy.
Lee YJ; Kim HK; Kim Y; Park SH; Lim JH; Jung J; Choi YS; Jo JC
Ann Hematol; 2024 Apr; ():. PubMed ID: 38678486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
